Document:

Description of Certain Compensatory Arrangements

 Exhibit 10.21 
 Description of Certain Compensatory Arrangements 
 Executive
Compensation 
 Varian Medical Systems, Inc. (the “Company”) does not have a written employment agreement with any
of its executive officers. The annual base salary for calendar year 2013 for each of the Company’s Principal Executive Officer, Principal Financial Officer, and certain executive officers (the “executive officers”) is as follows:

  

					
	 Name
	  	Base Salary	 
	 Dow R. Wilson,

        President and Chief Executive Officer
	  	$	900,000	  
	 Elisha W. Finney,

        Executive Vice President, Finance and Chief Financial
Officer
	  	$	573,735	  
	 Kolleen T. Kennedy,

        Senior Vice President and President, Oncology
Systems
	  	$	550,066	  
	 Robert H. Kluge,

        Senior Vice President and President, X-ray
Products
	  	$	463,316	  
	 John W. Kuo,

        Senior Vice President, General Counsel and Corporate
Secretary
	  	$	417,027	  

 On November 9, 2012, the Compensation and Management Development Committee (the “Compensation
Committee”) set the performance goals for fiscal year 2013 under the Company’s Management Incentive Plan (“MIP”) for the executive officers. The annual cash incentives under the MIP for the Company’s Section 16
executives, including the executive officers, are intended to comply with the exception for performance-based compensation under Section 162(m) of the Internal Revenue Code. For fiscal year 2013, the Compensation Committee established a
pool of funds equal to one and one-quarter percent (1.25%) of the Company’s fiscal year 2013 earnings before interest and taxes (“EBIT”) results (the “MIP Bonus Pool”) to be available for annual cash incentives under
the MIP to this group. The Compensation Committee has discretion to pay each of these executive officers less than their corresponding share of the MIP Bonus Pool. Such discretion shall be exercised by the Compensation Committee based on the
achievement of the following performance goals in fiscal year 2013 over fiscal year 2013 and any other factors determined by the Compensation Committee in its sole discretion. In the case of Mr. Wilson, Ms. Finney and Mr. Kuo,
payments under the MIP will be based 40% on EBIT growth for the Company as a whole, 20% on revenue growth for the Company as a whole, 20% on net orders growth for the Company as a whole, and 20% on the executive officer’s individual performance
and such other factors determined by the Compensation Committee in its sole discretion. In the case of Ms. Kennedy, payment under the MIP will be based 20% on EBIT growth for the Company as a whole, 10% on revenue growth for the Company as a
whole, 10% on net orders growth for the Company as a whole, 20% on EBIT growth for the Oncology Systems business segment, 10% on revenue growth for the Oncology Systems business segment, 10% on net orders growth for the Oncology Systems business
segment, and 20% on her individual performance and such other factors determined by the Compensation Committee in its sole discretion. In the case of Mr. Kluge, payment under the MIP will be based 20% on EBIT growth for the Company as a whole,
10% on revenue growth for the Company as a whole, 10% on net orders growth for the Company as a whole, 20% on EBIT growth for the X-ray Products business segment, 10% on revenue growth for the X-ray Products business segment, 10% on net orders
growth for the X-ray Products business segment, and 20% on his individual performance and such other factors determined by the Compensation Committee in its sole discretion. Payment under the MIP to the executive officers may vary from $0 to the
maximum of the lesser of two times the target participation level or a specified percentage of the MIP Bonus Pool based upon achievement under the performance goals described above. 

 Set forth below are payout levels for each executive officer if the target and maximum
levels under the MIP are achieved: 
  

													
	 Name
	  	Target	 	 	Maximum (the lesser of
the
following)	 
	 	  	As a %of
base salary	 	 	As a % of
base 
salary	 	 	As a % of MIP
Bonus Pool	 
	 Dow R. Wilson
	  	 	113	% 	 	 	226	% 	 	 	37	% 
	 Elisha W. Finney
	  	 	83	% 	 	 	166	% 	 	 	17	% 
	 Kolleen T. Kennedy
	  	 	83	% 	 	 	166	% 	 	 	17	% 
	 Robert H. Kluge
	  	 	78	% 	 	 	156	% 	 	 	13	% 
	 John W. Kuo
	  	 	68	% 	 	 	136	% 	 	 	10	% 

 These executive officers have also been extended certain perquisites, such as use of a leased automobile
under the Company’s Executive Car Program. Under the Executive Car Program, the Company provides a leased vehicle costing up to $82,000 for the Chief Executive Officer and leased vehicles costing up to $68,000 for the other executive officers.
Insurance, maintenance expenses and fuel costs are also included in the Executive Car Program. Participants have an option to purchase the car at the end of its three-year lease period or upon retirement at the lower of its depreciated book value or
its fair market value (based on the Kelley Blue Book Auto Market Report wholesale value). 
 The Company does not permit its
executive officers to use the Company’s fractionally owned aircraft for purely personal trips. However, the Company allows and includes in an executive officer’s compensation, as applicable, aircraft use attributable to permitted spousal
use of the fractionally owned aircraft for business purposes and spousal travel on commercial airplanes deemed valuable and appropriate for business purposes. 
 The Company reimburses executive officers and non-executive officers for financial planning, estate planning, tax planning, tax return preparation and financial counseling services (to a maximum of $6,500
per year and unlimited for the Chief Executive Officer). The Company also reimburses certain individuals, including all executive officers and non-executive officers, for annual medical examinations (up to a maximum of $4,000 per year). 

Additionally, for the benefit of the executive officers, the Company also provides a Company supplemental contribution match representing
retirement contributions which could not be contributed to the executive officers’ qualified retirement accounts due to Internal Revenue Code limitations. The Company also permits executive officers to participate in the Company’s Deferred
Compensation Plan, under which they may defer up to 50% of their base salaries and up to 100% of their cash incentives, and in compensation and benefit programs generally available to all other U.S. employees, such as the Company’s Employee
Stock Purchase Plan, 401(k) Retirement Program and supplemental life and disability insurance programs. Commencing in fiscal year 2013, the executive officers will not be eligible to participate in the Company’s Employee Incentive Plan.

 Compensation of Directors 
 Annual Cash Compensation.    Each non-employee director receives an annual retainer of $45,000, except that the lead director receives an annual retainer of $60,000, or in the
case of a new director or lead director a pro-rata portion thereof. The chairs of the Compensation and Management Development 

 
Committee and the Nominating and Corporate Governance Committee also receive an additional $10,000 annual retainer for serving in these positions, and the chair of the Audit Committee receives an
additional $15,000. Each non-employee director also receives $2,000 for each Board meeting attended ($1,000 if the Board meeting was an in-person meeting and the director attended by telephone or video conference), and $1,500 for each committee
meeting attended ($750 if the committee meeting was an in-person meeting and the director attended by telephone or video conference). Directors who are employees receive no compensation for their services as directors. All directors, however,
receive reimbursement for out-of-pocket expenses of the directors’ associated with attending Board and committee meetings and for expenses related to directors’ continuing education programs. Non-employee directors may elect to receive
cash compensation as full-value shares of the Company’s common stock, at a value equal to the fair market value of the Company’s common stock on the date that the foregone cash compensation otherwise would have been paid. Directors may
alternatively elect to defer their retainer and/or meeting fees under the Company’s Deferred Compensation Plan, subject to the restrictions of applicable tax laws. 
 Equity Compensation. New non-employee directors do not receive initial equity awards, but each continuing non-employee director receives an annual grant of non-qualified stock options to purchase
5,000 shares of common stock at an exercise price equal to the fair market value (i.e., the closing price) of the underlying shares of the Company’s common stock on the date of grant and an annual grant of Deferred Stock Units having a
fair market value on the date of grant of $100,000, based on the fair market value of the Company’s common stock on the date of grant (typically the date after the Company’s annual meeting of stockholders). 

Compensation for Levy as a Non-Executive Employee 
 In his role as a non-executive employee of the Company (and in addition to his responsibilities as Chairman of the Board), Dr. Levy provides on-going advice and counsel to the management of the
Company on strategic business and technological matters, and is involved with investor groups and key customers. In connection with this non-executive employee role, Dr. Levy receives the following compensation: 

 

	 	•	 	 base salary at a rate of $160,000 per annum; 

  

	 	•	 	 provision of a leased office space; 

  

	 	•	 	 provision of an administrator; and 

  

	 	•	 	 eligibility for the Corporation’s non-executive employee health and welfare benefit plans, subject to his election and contributions towards those
benefit plans, as well as the Employee Incentive Plan. 

 Dr. Levy is not eligible to participate in the
Company’s Management Incentive Plan and in any executive perquisite programs, including the Executive Car Program and reimbursement for executive physicals. He is also not eligible for equity awards, paid personal leave accrual or for any
supplemental retirement contributions in excess of the Company’s matching contributions under the Varian Medical Systems, Inc. Retirement Plan (the Company’s 401(k) Plan). He does not receive any separate compensation for his duties
serving on the Board. He receives the same reimbursement of expenses as do all other employees. 
 Compensation for Guertin
as a Non-Executive Employee 
 Effective at the end of fiscal year 2012, Mr. Guertin stepped down as the Company’s
President and CEO. He became our Vice Chairman, effective as of September 29, 2012. Mr. Guertin will continue as a non-executive employee of the Company until his retirement in February 2013. In his new role as a

 
non-executive employee of the Company (and in addition to his responsibilities as Vice Chairman of the Board), Mr. Guertin will provide on-going advice and counsel to our management on
strategic business and technological matters, will continue to be involved with industry and investor groups and key customers, and will provide transitional support. As a non-executive employee, Mr. Guertin will receive a base salary of
$952,711 per year. He will also participate in the MIP at a “target” participation level of 115% of annual salary in fiscal year 2013 and in the EIP, with any payouts based on fiscal year 2013 results and to be prorated up to
Mr. Guertin’s retirement date. He will further be entitled to participate in the DCP, including being eligible to receive Company Supplemental Contributions. In addition he will receive the following perquisites: (a) reimbursement for
up to $4,000 for annual medical examinations in January and February 2013 (plus up to $4,000 not to date reimbursed in calendar year 2012); (b) reimbursement for financial planning advice, estate planning advice, tax planning advice and/or tax
return preparation (no dollar limit); and (c) benefits equivalent to those offered under our Executive Car Program (subject to a vehicle purchase price limit of $82,000 and including the option to purchase the vehicle following his retirement).
We will also provide him with leased offsite office space at a fair market value not to exceed $7,000 per month and a part-time administrator. Mr. Guertin will also be eligible to participate in compensation and benefit programs generally
available to all other U.S. employees, 401(k) retirement plan and medical, dental, supplemental life and disability insurance programs, subject to his election and contributions towards those benefit programs, and receives the same reimbursement of
expenses as do all other employees. Mr. Guertin will not be eligible for the grant of equity awards in his capacity as an employee in fiscal year 2013. Mr. Guertin does not receive any separate compensation for his duties serving on the
Board. After Mr. Guertin retires, he will receive the same compensation as our other non-employee directors.Form of Registrant's Non-Employee Director Nonqualified Stock Option Agreement

 Exhibit 10.26 
 For use outside of U.S. except for Singapore 
 VARIAN MEDICAL SYSTEMS,
INC. 
 THIRD AMENDED AND RESTATED 
 2005 OMNIBUS STOCK PLAN 
 NON-EMPLOYEE DIRECTOR 

NONQUALIFIED STOCK OPTION AGREEMENT 
 Varian Medical Systems, Inc. (the “Company”) hereby grants you, «FNAME» «LNAME» (the “Director”), a nonqualified stock option under the Company’s Third
Amended and Restated 2005 Omnibus Stock Plan (the “Plan”), to purchase shares of common stock of the Company (“Shares”)*. The date of this Agreement is «GrantDate» (the “Grant Date”)*. In general, the
latest date this option will expire is «ExpirationDate» (the “Expiration Date”) as stated on the Grant Summary*. However, as provided in the attached Non-Employee Director, Terms and Conditions of Nonqualified Stock Option
(“Appendix A”), this option may expire earlier than the Expiration Date. Subject to the provisions of Appendix A and of the Plan, the principal features of this option are as follows: 

 

									
	 Maximum Number of Shares
 Purchasable with this Option:
	 	«Shares»	  		  	Purchase Price per share:	 	$«GrantPrice»
					
	Scheduled Vesting Date:	 		  		  	Number of Shares**:	 	
					
	«Grant Date»	 		  		  	«Shares»	 	

  

	*	See “Grant Summary” page on the service provider web-site. 

	**	Shares vest in whole share increments; fractions of shares vest only when they equal whole share increments. 

 

			
	 Event Triggering

Termination of Option:
	  	 Maximum Time to Exercise
 After Triggering Event***:

	Termination of Service due to Disability	  	                3 years
	Termination of Service due to Retirement	  	                3 years
	Termination of Service due to death	  	                3 years
	Termination of Service due to completion of term as Director	  	                3 years
	All other Terminations of Service	  	                3 months

  

	***	However, in no event may this option be exercised after the Expiration Date (except in certain cases of the death of the Director). 

Your acceptance online at the service provider web-site or, when provided, your signature on a copy of this Nonqualified Stock Option
Agreement, indicates your agreement and understanding that this option is subject to all of the terms and conditions contained in Appendix A and the Plan. For example, important additional information on vesting and termination of this option is
contained in Paragraphs 4 through 6 of Appendix A. ACCORDINGLY, PLEASE BE SURE TO READ ALL OF APPENDIX A AND THE PLAN, WHICH CONTAIN THE SPECIFIC TERMS AND CONDITIONS OF THIS OPTION. YOU CAN REQUEST A COPY OF THE PLAN BY CONTACTING THE
CORPORATE HUMAN RESOURCES OFFICE IN PALO ALTO, CALIFORNIA. 

  
 1 

 For use outside of U.S. except for Singapore 

APPENDIX A 

Non-Employee Director 
 TERMS AND CONDITIONS OF NONQUALIFIED STOCK OPTION 
 1. Grant of Option. The
Company hereby grants to the Director under the Plan, as a separate incentive in connection with his or her service and not in lieu of any other compensation for his or her services, a nonqualified stock option to purchase, on the terms and
conditions set forth in this Agreement and the Plan, all or any part of an aggregate of Shares Granted as specified on the “Grant Summary” page of the service provider web-site. This option is not intended to qualify as an “incentive
stock option” under Section 422 of the Internal Revenue Code of 1986, as amended. 
 2. Exercise Price. The
purchase price per Share for this option (the “Exercise Price”) shall be the Grant Price in USD as specified on the “Summary of Grant Award” page of the service provider web-site, which is the Fair Market Value of a Share on the
Grant Date. 
 3. Number of Shares. The number and class of Shares specified in Paragraph 1 above, and/or the
Exercise Price, are subject to adjustment by the Board of Directors of the Company (the “Board”) in the event of any merger, reorganization, consolidation, recapitalization, separation, liquidation, stock dividend, split-up, Share
combination or other change in the corporate structure of the Company affecting the Shares. 
 4. Vesting Schedule. The
right to exercise this option is scheduled to vest fully as of the Grant Date. 
 5. Expiration of Option. In the event
of the Director’s Termination of Service for any reason other than Disability, Retirement, completion of term as a Director or death, the Director may, within three (3) months after the date of such Termination, or prior to the Expiration
Date, whichever shall first occur, exercise this option. In the event of the Director’s Termination of Service due to Disability, or completion of term as a Director, Retirement, the Director may, within three (3) years after the date of
such Termination, or prior to the Expiration Date, whichever shall first occur, exercise this option. 
 6. Death of
Director. In the event that the Director dies while in the employ of the Company or during the three (3) month or three (3) year periods referred to in Paragraph 5 above, the Director’s designated beneficiary, or if either no
beneficiary survives the Director or the Board does not permit beneficiary designations, the administrator or executor of the Director’s estate, may, within three (3) years after the date of death, or prior to the Expiration Date,
whichever shall first occur, exercise this option. Any such transferee must furnish the Company (a) written notice of his or her status as a transferee, (b) evidence satisfactory to the Company to establish the validity of the transfer of
this option and compliance with any laws or regulations pertaining to such transfer, and (c) written acceptance of the terms and conditions of this option as set forth in this Agreement. 

7. Persons Eligible to Exercise Option. This option shall be exercisable during the Director’s lifetime only by the Director.
The option shall not be transferable by the Director, except by (a) a valid beneficiary designation made in a form and manner acceptable to the Board, or (b) will or the applicable laws of descent and distribution. 

  
 A-1

 8. Exercise of Option. This option may be exercised by the person then entitled to do
so as to any Shares which may then be purchased (a) by giving written notice of exercise to the Secretary of the Company (or his or her designee), specifying the number of full Shares to be purchased and accompanied by full payment of the
Exercise Price (and the amount of any income or other taxes or social contributions the Company determines is required to be withheld by reason of such exercise, as described in Section 17 below), and (b) by giving satisfactory assurances
in writing if requested by the Company, signed by the person exercising the option, that the Shares to be purchased upon such exercise are being purchased for investment and not with a view to the distribution thereof. In the absolute discretion of
the Board, the person entitled to exercise the option may elect to satisfy the tax withholding requirement described in subparagraph (a) above (determined at the applicable minimum rates to the extent required to avoid adverse accounting
consequences) by having the Company withhold Shares or delivering to the Company already-owned Shares. No partial exercise of this option may be for less than ten (10) Share lots or multiples thereof. 

9. Suspension of Exercisability. If at any time the Company shall determine, in its discretion, that the listing, registration or
qualification of the Shares upon any securities exchange or under any state or federal law, or the consent or approval of any governmental regulatory authority, is necessary or desirable as a condition of the purchase of Shares hereunder, this
option may not be exercised, in whole or in part, unless and until such listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Company. The Company shall make
reasonable efforts to meet the requirements of any such state or federal law or securities exchange and to obtain any such consent or approval of any such governmental authority. Notwithstanding anything else this Agreement, the Company
reserves the right to impose other requirements on the Director’s participation in the Plan or on the option and any Shares acquired under the Plan to the extent the Company determines it is necessary or advisable in order to comply with
applicable law or to facilitate the administration of the Plan and to require the Director to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. The Director understands that the laws of the country in
which he/she is residing at the time of grant, vesting, and/or exercise of this option (including any rules or regulations governing securities, foreign exchange, tax, labor or other matters) may restrict or prevent exercise of this option or may
subject the Director to additional procedural or regulatory requirements he/she is solely responsible for and will have to independently fulfill in relation to the exercise of the Option. Such restrictions, procedures, requirements, terms, and
conditions may be set forth (but are not limited to those) in an appendix hereto, which constitutes part of this Agreement. 

10. No Rights of Stockholder. Neither the Director (nor any beneficiary) shall be or have any of the rights or privileges of a
stockholder of the Company in respect of any of the Shares issuable pursuant to the exercise of this option, unless and until certificates representing such Shares shall have been issued, recorded on the records of the Company or its transfer agents
or registrars, and delivered to the Director (or beneficiary). 
 11. Service Acknowledgments. Nothing in this Agreement
or the Plan shall confer upon the Director any right to continue service on the Board of the Company or its Subsidiaries (as the case may be). In addition, the Director acknowledges and agrees to the following: 

(a) The Plan is discretionary in nature and the Company may amend, suspend, or terminate it at any time; 

  
 A-2

 (b) The grant of this option is voluntary and occasional and does not create any contractual
or other right to receive future grants of options, or benefits in lieu of the option even if the option has been granted repeatedly in the past; 
 (c) All determinations with respect to such future options, if any, including but not limited to, the times when the options shall be granted or when the options shall vest, will be at the sole discretion
of the Board; 
 (d) The Director’s participation in the Plan is voluntary; 

(e) The value of this option is an extraordinary item of compensation, which is outside the scope of the Director’s service contract
(if any), except as may otherwise be explicitly provided in the Director’s service contract (if any); 
 (f) This option is
not part of normal or expected compensation for any purpose, including, but not limited to, calculating termination, severance, resignation, redundancy, end of service, or similar payments, or bonuses, long-service awards, pension or retirement
benefits; 
 (g) The future value of the Shares is unknown and cannot be predicted with certainty; 

(h) No claim or entitlement to compensation or damages arises from the termination of the Option or diminution in value of the Option or
Shares and the Director irrevocably release the Company and its Subsidiaries from any such claim that may arise. 
 (i) Neither
the Plan nor this option shall be construed to create an employment or service relationship where any such relationship did not otherwise already exist. 
 12. Address for Notices. Any notice to be given to the Company under the terms of this Agreement shall be addressed to the Company, in care of its Secretary at 3100 Hansen Way, Palo Alto,
California 94304, or at such other address as the Company may hereafter designate in writing. 
 13. Option is Not
Transferable. Except as otherwise expressly provided herein, this option and the rights and privileges conferred hereby may not be transferred, pledged, assigned or otherwise hypothecated in any way (whether by operation of law or otherwise) and
shall not be subject to sale under execution, attachment or similar process. Upon any attempt to transfer, pledge, assign, hypothecate or otherwise dispose of this option, or of any right or privilege conferred hereby, or upon any attempted sale
under any execution, attachment or similar process, this option and the rights and privileges conferred hereby immediately shall become null and void. 
 14. Maximum Term of Option. Notwithstanding any other provision of this Agreement, this option is not exercisable after the Expiration Date. 

15. Binding Agreement. Subject to the limitation on the transferability of this option contained herein, this Agreement shall be
binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. 

  
 A-3

 16. Conditions to Exercise. The Exercise Price for this option must be paid in the
legal tender of the United States (including, in the Board’s sole discretion, by means of a broker-assisted cashless exercise) or, in the Board’s sole discretion, in Shares of equivalent value that (a) were previously issued to the
Director and (b) have been held by the Director for at least six (6) months prior thereto (to the extent required to avoid adverse accounting consequences). Exercise of this option will not be permitted until satisfactory arrangements have
been made for the payment of the appropriate amount of withholding taxes (as determined by the Company and as further described in Section 17 below). If the Director fails to remit to the Company such withholding amount within the time period
specified by the Board (in its discretion), the award may be forfeited and in such case the Director shall not receive any of the Shares subject to this Agreement. Any cross-border remittance made to exercise this option (or to transfer proceeds
received upon the sale of Shares) must be made through a locally authorized financial institution or registered foreign exchange agency and may require the Director to provide such entity with certain information regarding the transaction. The
Director understands and agrees that the Company is neither responsible for any foreign exchange fluctuations between the Director’s local currency and the United States Dollar that may affect the value of this option nor liable for any
decrease in the value of this option or the underlying Shares. 
 17. Tax Liability. The Company and any of its
Subsidiaries shall assess any required tax and social insurance contribution liability and requirements in connection with the Director’s participation in the Plan, including, without limitation, tax liability and social insurance contribution
liability associated with the grant or exercise of the option or sale of the underlying Shares (the “Tax Liability”). These requirements may change from time to time as laws or interpretations change. Regardless of the Company’s or
any Subsidiary’s actions in this regard, the Director hereby acknowledges and agrees that the Tax Liability shall be the Director’s ultimate responsibility and liability. The Director agrees as a condition of his or her participation in
the Plan to make arrangements satisfactory to the Company and its Subsidiary to enable it to satisfy any withholding, payment and/or collection requirements associated with the satisfaction of the Tax Liability, including authorizing the Company or
the Subsidiary to: (i) withhold all applicable amounts from the Director’s wages or other cash compensation due to the Director, in accordance with any requirements under the laws, rules, and regulations of the country of which the
Director is a resident, and (ii) act as the Director’s agent to sell sufficient Shares for the proceeds to settle such requirements. Furthermore, the Director agrees to pay the Company or the Subsidiary any amount the Company or any
Subsidiary may be required to withhold, collect or pay as a result of the Director’s participation in the Plan or that cannot be satisfied by deduction from the Director ‘s wages or other cash compensation paid to the Director by the
Company or the Subsidiary or sale of the Shares acquired under the Plan. The Director acknowledges that he or she may not participate in the Plan and the Company and the Subsidiary shall have no obligation to deliver Shares until the Tax Liability
has been satisfied by the Director. 
 18. Data Protection. The Director hereby explicitly and unambiguously
consents to the collection, use and transfer, in electronic or other form, of his or her personal data by and among, as applicable, the Company and any Subsidiary for the exclusive purpose of implementing, administering and managing the
Director’s participation in the Plan. The Director understands that the Company and its Subsidiaries may hold certain personal information about the Director including, but not limited to, the Director’s name, home address and telephone
number, date of birth, social security number (or any other social or national identification number), salary, nationality, job title, number of Shares held and the details of the Option or any other entitlement to Shares awarded, cancelled, vested,
unvested or outstanding for the purpose of implementing, administering and managing the Director’s participation in the Plan (the “Data”). The Director understands that the Data may be

  
 A-4

 
transferred to the Company or any Subsidiaries, or to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in the
Director’s country or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than the Director’s country. The Director understands that he or she may request a list
with the names and addresses of any potential recipients of the Data by contacting the Company. The Director authorizes the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of
implementing, administering and managing his or her participation in the Plan, including any requisite transfer of such Data to a broker or other third party assisting with the administration of the option under the Plan or with whom Shares acquired
pursuant to the exercise of the option or cash from the sale of such Shares may be deposited. Furthermore, the Director acknowledges and understands that the transfer of the Data to the Company or Subsidiaries or to any third parties is necessary
for his or her participation in the Plan. The Director understands that Data will be held only as long as is necessary to implement, administer and manage his or her participation in the Plan. The Director further acknowledges that withdrawal of
consent may affect his or her ability to vest in, exercise or realize benefits from the option, and his or her ability to participate in the Plan. For more information on the consequences of refusal to consent or withdrawal of consent, the Director
understands that he or she may contact the Company. 
 19. Plan Governs. This Agreement is subject to all of the
terms and provisions of the Plan. In the event of a conflict between one or more provisions of this Agreement and one or more provisions of the Plan, the provisions of the Plan shall govern. Capitalized terms and phrases used and not defined in this
Agreement shall have the meaning set forth in the Plan. 
 20. Governing Law and Forum. This Agreement shall be governed
by and construed in accordance with the laws of the State of California, without reference to its principles of conflicts of law. The parties agree that any action or proceeding arising from or relating to this Agreement must be brought exclusively
in a court of competent jurisdiction, federal or state, located in California and in no other jurisdiction. 
 21. Compliance
with Laws and Regulations. The Director understands that the grant, vesting and exercise of this option under the Plan and the issuance, transfer, assignment, sale, or other dealings of the Shares shall be subject to compliance by the Company
(and its Subsidiaries) and the Director with all applicable laws, rules, and regulations. Furthermore, the Director agrees that he or she will not acquire Shares pursuant to the Plan except in compliance with all applicable laws, rules and
regulations. 
 22. Board Authority. The Board shall have all discretion, power, and authority to interpret the Plan and
this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith. All actions taken and all interpretations and determinations made by the Board in good faith shall be final and
binding upon the Director, the Company and all other interested persons, and shall be given the maximum deference permitted by law. No member of the Board shall be personally liable for any action, determination or interpretation made in good faith
with respect to the Plan or this Agreement. 
 23. Captions. The captions provided herein are for convenience only and
are not to serve as a basis for the interpretation or construction of this Agreement. 
 24. Agreement Severable. In the
event that any provision in this Agreement shall be held invalid or unenforceable, such provision shall be severable from, and such invalidity or unenforceability shall not be construed to have any effect on, the remaining provisions of this
Agreement. 

  
 A-5

 25. Modifications to the Agreement. This Agreement constitutes the entire
understanding of the parties on the subjects covered. The Director expressly warrants that he or she is not executing this Agreement in reliance on any promises, representations, or inducements other than those contained herein. Modifications to
this Agreement or the Plan can be made only in an express written contract executed by a duly authorized officer of the Company. 
 26. Communications, Electronic Delivery and Execution. The Company may, in its sole discretion, decide to deliver any documents related to options awarded under the Plan or future options that may
be awarded under the Plan by electronic means or request Director’s consent to participate in the Plan by electronic means. The Director hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan
through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. Electronic execution of this Agreement and/or other documents shall have the same binding effect as a written or hard
copy signature and accordingly, shall bind the Director and the Company to all of the terms and conditions set forth in the Plan, this Agreement and/or such other documents. To the extent the Director has been provided with a copy of this Agreement,
the Plan, or any other documentation relating to the option in a language other than English, the English language documents will prevail in case of ambiguities or divergences as a result of translation. 

  
 A-6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}]]